Day One
Tuesday 23rd February, 2016
Day Two
Wednesday 24th February, 2015
08:50 Chair’s Opening Remarks
Driving Success in Neurodegenerative Drug Development: Reinventing Clinical Trials
09:00 Applying Translational Research to Early Clinical Development: Improving the Progression of Candidates for Neurodegeneration
Synopsis
• The importance of target engagement biomarkers to enable quick kill decisions
• Incorporating innovative biomarkers to optimize early clinical trials
• Utilizing adaptive clinical trial design to enable seamless transitions between clinical trial phases
• Maximizing confidence of therapeutic efficacy through initial trials in well defined and relevant populations
09:20 Delayed-Start Clinical Studies: Reflections & Lessons from the ADAGIO Study
Synopsis
• The challenge of symptomatic effect vs. disease modification
• A variety of perspectives on the practicalities of delayed start design
• Interpreting the results to tease out what lies beyond the symptoms
• Analyzing the totality of data to define the outcomes and implications of CNS clinical trials
09:40 Panel Discussion: Revolutionizing Clinical Trial Design to Improve the Progression of Neurodegenerative Therapeutics Through to the Clinic
Synopsis
• Building upon previous experiences to inspire the future of clinical trial design
• Engaging experts in neurodegenerative clinical trial organisation to make future studies faster, cheaper, lower risk and ultimately more successful
• Harnessing target engagement and quantitative systems pharmacology data to drive clinical trial success
• Debating the drug regulatory approval pathway for neurodegenerative therapeutics
10:30 Morning Refreshments & Networking
11:00 Harnessing the Full Potential of Big Data & Digital Health for More Efficient Clinical Trials
Synopsis
• Utilizing data sharing and digital health to successfully design and execute clinical trial programs
• How statistical analysis and modelling can reinvent your approach to clinical trials
• Synergizing data and biomarkers to identify patient populations with specific neuropathology for appropriate use as clinical subjects
11:30 Mobile Health: Perspectives on Potential Utility in Neuroscience Early Development
Synopsis
• Understanding what mobile health is
• Utilizing wearable sensors in clinical trials
• Sensors and devices as pharmacodynamic and safety biomarkers
• Potential applications of mobile health in neuroscience
Revolutionizing Therapeutic Strategies for Neurodegenerative Treatments
12:00 Addressing the Therapeutic Landscape in Parkinson’s Disease
Synopsis
• Evaluating the next generation of targets for the production of diseasemodifying therapies
• Harnessing the full potential of drug repurposing for the Parkinson’s Disease clinical pipeline
• Devising clinical strategies for combinatorial drug therapeutics
12:30 Networking Lunch
13:30 How to Apply Our Knowledge of Genetic Drivers in Parkinson’s Disease to Progress the Development of Novel Therapeutics
Synopsis
• How to use genetic data to drive novel pathway and target selection
• Using genetic profiles to identify higher risk patient populations in earlier phases of disease
• Innovating new methods to target genetic causes of neurodegenerative diseases
• The role of GBA and LRRK2 in sporadic Parkinson’s disease
14:00 Defining the Future of Neurodegenerative Therapeutics: Neuroinflammation & the Immune System
Synopsis
• Understanding the pathological role of neuroinflammation and the immune system in the development of neurodegenerative diseases
• Defining dynamic therapeutic strategies for tackling neuroinflammation
• How genetics can drive the identification of novel targets for immune based therapy in neurodegenerative disorders
• Strategies to bridge the gap between mechanistic understanding and disease phenotype
14:30 BACE Inhibitors: The Statins of Neurodegeneration?
Synopsis
• Understanding the current progress of BACE inhibitors through clinical trials
• Identifying strategies for the application of BACE inhibitor therapeutics to pave the way for preventative medicine in neurodegenerative disorders
• Looking forward to the next generation: how we can develop more therapeutically efficient BACE inhibitors
• Evaluating the blockbuster potential of BACE inhibitors
15:00 Afternoon Refreshments & Networking
15:30 Panel Discussion: The Past, Present & Future in Neurodegenerative Therapeutics • Debating the Amyloid Beta hypothesis: Is Amyloid
Synopsis
• Debating the Amyloid Beta hypothesis: is Amyloid Beta the holy grail of treatment targets?
• Applying the combinatorial therapy paradigm: neurodegenerative therapeutic strategies stuck in the dark ages?
• Preclinical and clinical funding strategies to maximize resources for drug discovery and development
• Unifying degeneration: universal strategies for approaching drug discovery and development
• Future potential: a multitude of human data modalities driving the future of the R&D landscape